The epidemiology of nonâ€alcoholic fatty liver disease

Liver International

37, 81-84

DOI: 10.1111/liv.13299

Citation Report

#	Article	IF	Citations
1	Recent advances in hepatology. Liver International, 2017, 37, 3-6.	1.9	4
2	Non-alcoholic fatty liver disease (NAFLD) â€“ pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metabolism Reviews, 2017, 49, 197-211.	1.5	414
3	Protective effect of Hua Tan Qu Shi decoction against liver injury in rats with nonalcoholic fatty liver disease. Biomedicine and Pharmacotherapy, 2017, 91, 181-190.	2.5	8
4	EASLâ€“EASDâ€“EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. Diabetologia, 2017, 60, 1218-1222.	2.9	95
5	Modulation of Gut Microbiota in Pathological States. Engineering, 2017, 3, 83-89.	3.2	26
6	Nonâ€alcoholic fatty liver disease â€“ histological scoring systems: a large cohort singleâ€center, evaluation study. Apmis, 2017, 125, 962-973.	0.9	45
7	Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis. Scientific Reports, 2017, 7, 12361.	1.6	81
8	The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control, 2017, 24, 107327481772924.	0.7	66
9	Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian Journal of Gastroenterology, 2017, 36, 390-399.	0.7	40
10	Animal models for analyzing metabolic syndromeâ€associated liver diseases. Pathology International, 2017, 67, 539-546.	0.6	28
11	Need to Face Liver Cirrhosis after HCV Cure with Antivirals. EBioMedicine, 2017, 24, 24-25.	2.7	6
12	Gankyrin induces <scp>STAT</scp>3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Science, 2017, 108, 1996-2003.	1.7	40
13	Increased incidence of nonâ€alcoholic fatty liver disease in male rat offspring exposed to fluoxetine during fetal and neonatal life involves the NLRP3 inflammasome and augmented de novo hepatic lipogenesis. Journal of Applied Toxicology, 2017, 37, 1507-1516.	1.4	8
14	Incidental Findings on Myocardial Perfusion SPECT Images. Journal of Nuclear Medicine Technology, 2017, 45, 175-180.	0.4	11
15	Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study. Breast Cancer Research and Treatment, 2017, 166, 289-297.	1.1	17
16	Silymarin for Treatment of Nonalcoholic Steatohepatitisâ€“A New Kid on the Block?. Clinical Gastroenterology and Hepatology, 2017, 15, 1863-1865.	2.4	0
17	Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today, 2017, 22, 1707-1718.	3.2	178
18	Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: a pilot study. Lipids in Health and Disease, 2017, 16, 129.	1.2	22

#	Article	IF	Citations
20	Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients, 2017, 9, 870.	1.7	102
21	Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Nutrients, 2017, 9, 1065.	1.7	49
22	Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-7.	1.9	30
23	Nonalcoholic fatty liver disease: Evolving paradigms. World Journal of Gastroenterology, 2017, 23, 6571-6592.	1.4	138
24	Lipids: Evergreen autofluorescent biomarkers for the liver functional profiling. European Journal of Histochemistry, 2017, 61, 2808.	0.6	7
25	Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. PLoS ONE, 2017, 12, e0176416.	1.1	65
26	PNPLA3 expression and its impact on the liver: current perspectives. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 55-66.	0.9	58
27	Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatobiliary Surgery and Nutrition, 2017, 6, 350-352.	0.7	4
28	Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World Journal of Clinical Oncology, 2017, 8, 429-436.	0.9	73
29	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. Journal of Human Genetics, 2018, 63, 621-626.	1.1	29
30	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones, 2018, 17, 219-229.	0.9	37
31	Protective effect of curcumin on the liver of high fat diet-fed rats. Gene Reports, 2018, 11, 18-22.	0.4	10
32	Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biology, 2018, 15, 467-479.	3.9	196
33	Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the â€˜intelligent LFTâ€™ pathway for the automated assessment of deranged liver enzymes. Frontline Gastroenterology, 2018, 9, 175-182.	0.9	10
34	Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy. Current Opinion in Gastroenterology, 2018, 34, 90-96.	1.0	33
35	Transporterâ€Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate. Clinical Pharmacology and Therapeutics, 2018, 104, 749-756.	2.3	41
36	Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 431-440.	1.8	13
37	Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 819-830.	1.8	22

#	Article	IF	Citations
38	The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. European Journal of Surgical Oncology, 2018, 44, 195-208.	0.5	66
39	Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease. Endocrinology, 2018, 159, 20-31.	1.4	60
40	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (United States), 2018, 97, e0214.	0.4	143
41	Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Molecular Metabolism, 2018, 13, 56-66.	3.0	65
42	New therapeutic perspectives in non-alcoholic steatohepatitis. GastroenterologÃa Y HepatologÃa (English Edition), 2018, 41, 128-142.	0.0	0
43	Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2018, 22, 93-108.	1.0	39
44	Weight loss enhances hepatic antioxidant status in a NAFLD model induced by high-fat diet. Applied Physiology, Nutrition and Metabolism, 2018, 43, 23-29.	0.9	11
45	Nuevas perspectivas terapÃ©uticas en la esteatohepatitis no alcohÃ³lica. GastroenterologÃa Y HepatologÃa, 2018, 41, 128-142.	0.2	10
46	Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sciences, 2018, 192, 46-54.	2.0	86
47	Epigenetically mediated inhibition of Sâ€adenosylhomocysteine hydrolase and the associated dysregulation of 1â€carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma. FASEB Journal, 2018, 32, 1591-1601.	0.2	23
48	Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition, 2018, 58, 3141-3158.	5.4	74
49	Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKÎ± in the liver. Molecular Medicine Reports, 2018, 17, 6840-6846.	1.1	13
50	The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. Medicine (United) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		11
51	Oncogenic Secretory Clusterin: A Promising Therapeutic Target for Hepatocellular Carcinoma. , 0, , .		0
52	Apoptosis and non-alcoholic fatty liver diseases. World Journal of Gastroenterology, 2018, 24, 2661-2672.	1.4	189
53	Attenuation by Tetrahydrocurcumin of Adiposity and Hepatic Steatosis in Mice with High-Fat-Diet-Induced Obesity. Journal of Agricultural and Food Chemistry, 2018, 66, 12685-12695.	2.4	28
54	Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV monoâ€infection under longâ€term combined antiretroviral therapy. Journal of the International AIDS Society, 2018, 21, e25201.	1.2	46
55	Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. PLoS ONE, 2018, 13, e0204308.	1.1	17

#	Article	IF	Citations
56	Mechanisms involved in the death of steatotic WIF-B9 hepatocytes co-exposed to benzo[a]pyrene and ethanol: a possible key role for xenobiotic metabolism and nitric oxide. Free Radical Biology and Medicine, 2018, 129, 323-337.	1.3	8
57	A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	44
58	The effects of metabolic status on nonâ€alcoholic fatty liver diseaseâ€related outcomes, beyond the presence of obesity. Alimentary Pharmacology and Therapeutics, 2018, 48, 1260-1270.	1.9	70
59	How Much Ischemia Can the Severely Steatotic Rat Liver Tolerate?. In Vivo, 2018, 32, 1381-1386.	0.6	4
60	Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-9.	0.8	78
61	Sex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats. Biology of Sex Differences, 2018, 9, 40.	1.8	9
62	Role of Inflammasomes in the Development of Gastrointestinal Diseases. Experientia Supplementum (2012), 2018, 108, 235-268.	0.5	1
63	Possible Involvement of Mitochondrial Dysfunction and Oxidative Stress in a Cellular Model of NAFLD Progression Induced by Benzo[a]pyrene/Ethanol CoExposure. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-18.	1.9	32
64	The association between missing teeth and nonâ€alcoholic fatty liver disease in adults. Journal of Clinical Periodontology, 2018, 45, 941-951.	2.3	14
65	Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and metaâ€analysis of clinical trials. Phytotherapy Research, 2018, 32, 1876-1884.	2.8	37
66	Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates. Journal of Biological Chemistry, 2018, 293, 11944-11954.	1.6	37
67	Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?. Advances in Experimental Medicine and Biology, 2018, 1061, 63-77.	0.8	6
68	Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). PLoS ONE, 2018, 13, e0199294.	1.1	15
69	A Controlled Fermented Samjunghwan Herbal Formula Ameliorates Non-alcoholic Hepatosteatosis in HepG2 Cells and OLETF Rats. Frontiers in Pharmacology, 2018, 9, 596.	1.6	14
70	Phenotypical heterogeneity in responder and nonresponder male ApoE*3Leiden.CETP mice. American Journal of Physiology - Renal Physiology, 2018, 315, G602-G617.	1.6	10
71	Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo. Scientific Reports, 2018, 8, 5963.	1.6	36
72	Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Medicine (United States), 2018, 97, e0462.	0.4	29
73	Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. World Journal of Gastroenterology, 2018, 24, 461-474.	1.4	8

#	Article	IF	Citations
74	Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutrition Reviews, 2018, 76, 581-602.	2.6	88
75	Does Turmeric/curcumin Supplementation Change Anthropometric Indices in Patients with Non-alcoholic Fatty Liver Disease? A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Nutrition Research, 2019, 8, 196.	0.5	18
76	Integrin Î²1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. Journal of Hepatology, 2019, 71, 1193-1205.	1.8	112
77	Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. Journal of Steroid Biochemistry and Molecular Biology, 2019, 194, 105445.	1.2	24
78	Liver enzymes and allâ€cause mortality: Open issues. Liver International, 2019, 39, 1389-1390.	1.9	2
79	The Effect of 30-minute Ischemia on the Levels of IL6, TNFÎ±, NO, Glutathione and Lactic Acid in the Hepatic Tissue of Rats with Hepatic Steatosis. Hellenike Cheirourgike Acta Chirurgica Hellenica, 2019, 91, 65-74.	0.1	1
80	Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study. BMC Gastroenterology, 2019, 19, 126.	0.8	17
81	Progress and prospects for treating ataxia telangiectasia. Expert Opinion on Orphan Drugs, 2019, 7, 233-251.	0.5	5
82	Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease: Evaluation of four MR techniques versus biopsy. European Journal of Radiology, 2019, 118, 169-174.	1.2	17
83	Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placeboâ€controlled, doubleâ€blind clinical trial. Phytotherapy Research, 2019, 33, 2118-2125.	2.8	51
84	Comparison of nonâ€invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. Hepatology Research, 2019, 49, 1305-1315.	1.8	12
85	Body weight-dependent and independent improvement in lipid metabolism after Roux-en-Y gastric bypass in ApoE*3Leiden.CETP mice. International Journal of Obesity, 2019, 43, 2394-2406.	1.6	4
86	Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis. Frontiers in Pharmacology, 2019, 10, 1129.	1.6	14
87	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. International Journal of Molecular Sciences, 2019, 20, 5037.	1.8	98
88	RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease. International Journal of Endocrinology, 2019, 2019, 1-11.	0.6	28
89	Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet. PLoS ONE, 2019, 14, e0221455.	1.1	13
90	Inactivation of the superoxide dismutase by malondialdehyde in the nonalcoholic fatty liver disease: a combined molecular docking approach to clinical studies. Archives of Physiology and Biochemistry, 2021, 127, 557-564.	1.0	26
91	Interleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases. Frontiers in Immunology, 2019, 10, 2014.	2.2	100

#	Article	IF	Citations
92	Automated Liver Fat Quantification at Nonenhanced Abdominal CT for Population-based Steatosis Assessment. Radiology, 2019, 293, 334-342.	3.6	91
93	Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in the Chinese Han population. Lipids in Health and Disease, 2019, 18, 170.	1.2	12
94	Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers. Current HIV Research, 2019, 17, 173-182.	0.2	6
95	Multiparametric ultrasound in liver diseases: an overview for the practising clinician. Postgraduate Medical Journal, 2019, 95, 425-432.	0.9	19
96	Consenso mexicano de la enfermedad por hÃgado graso no alcohÃ³lico. Revista De GastroenterologÃa De MÃ©xico, 2019, 84, 69-99.	0.4	26
97	Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care. Journal of Hepatology, 2019, 71, 699-706.	1.8	45
98	Acupuncture Regulating Gut Microbiota in Abdominal Obese Rats Induced by High-Fat Diet. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-12.	0.5	29
99	The effects of oleoylethanolamide, an endogenous PPARâ€Î± agonist, on risk factors for NAFLD: A systematic review. Obesity Reviews, 2019, 20, 1057-1069.	3.1	35
100	Metabolic Syndrome in Patients with Non-alcoholic Fatty Liver Disease: A Community Based Cross-sectional study. Cureus, 2019, 11, e4099.	0.2	10
101	Bromide alleviates fatty acidâ€induced lipid accumulation in mouse primary hepatocytes through the activation of PPARÎ± signals. Journal of Cellular and Molecular Medicine, 2019, 23, 4464-4474.	1.6	8
102	In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metabolic Syndrome and Related Disorders, 2019, 17, 289-295.	0.5	16
103	Significant changes in hepatic transcriptome and circulating miRNAs are associated with dietâ€induced metabolic syndrome in apoE3L.CETP mice. Journal of Cellular Physiology, 2019, 234, 20485-20500.	2.0	6
104	Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients, 2019, 11, 872.	1.7	159
105	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2093-2100.e3.	2.4	33
106	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. , 2019, , 245-274.		0
107	Hepatic Steatosis Assessment Using Quantitative Ultrasound Parametric Imaging Based on Backscatter Envelope Statistics. Applied Sciences (Switzerland), 2019, 9, 661.	1.3	21
108	Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. Journal of Endocrinological Investigation, 2019, 42, 1099-1107.	1.8	13
109	Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer, 2019, 19, 185.	1.1	191

#	Article	IF	Citations
110	Adipocytes as lipid sensors of oleic acid transport through a functional Caco-2/HT29-MTX intestinal barrier. Adipocyte, 2019, 8, 83-97.	1.3	8
111	Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in nonâ€obese HIVâ€infected patients. Liver International, 2019, 39, 1514-1520.	1.9	16
112	Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. , 2019, 199, 164-172.		49
113	The Mexican consensus on nonalcoholic fatty liver disease. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2019, 84, 69-99.	0.1	6
114	Exposure to air pollution during pregnancy and newborn liver function. Chemosphere, 2019, 226, 447-453.	4.2	42
115	Interaction BetweenAGTR1andPPARÎ³Gene Polymorphisms on the Risk of Nonalcoholic Fatty Liver Disease. Genetic Testing and Molecular Biomarkers, 2019, 23, 166-175.	0.3	5
116	Role of gut microbiota in the development of non-alcoholic fatty liver disease. Liver Research, 2019, 3, 25-30.	0.5	10
117	The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites, 2019, 9, 25.	1.3	7
118	YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. International Journal of Molecular Sciences, 2019, 20, 638.	1.8	44
119	Protective Actions of Polyphenols in the Development of Nonalcoholic Fatty Liver Disease. , 2019, , 91-99.		3
120	Calorie Restriction in Adulthood Reduces Hepatic Disorders Induced by Transient Postnatal Overfeeding in Mice. Nutrients, 2019, 11, 2796.	1.7	19
121	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expression, 2019, 19, 175-185.	0.5	20
122	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Scientific Reports, 2019, 9, 20126.	1.6	6
123	Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. Scientific Reports, 2019, 9, 17463.	1.6	21
124	Dysregulation of Bile Acids in Patients with NAFLD. , 0, , .		2
125	Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease (NAFLD) with Lipopolysaccharides (LPS) Secretion. Diagnostics, 2019, 9, 205.	1.3	19
126	Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology, 2019, 20, 189-197.	0.4	1
127	Exercise Programming for Nonalcoholic Fatty Liver Disease. Strength and Conditioning Journal, 2019, 41, 89-93.	0.7	2

#	Article	IF	Citations
128	Green Tea Prevents NAFLD by Modulation of miR-34a and miR-194 Expression in a High-Fat Diet Mouse Model. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-18.	1.9	37
129	Hepatocellular carcinoma in the noncirrhotic liver: a literature review. European Journal of Gastroenterology and Hepatology, 2019, 31, 743-748.	0.8	16
130	Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method. Nutrition Research, 2019, 63, 95-105.	1.3	3
131	Histopathological and biochemical changes in the development of nonalcoholic fatty liver disease induced by high-sucrose diet at different times. Canadian Journal of Physiology and Pharmacology, 2019, 97, 23-36.	0.7	9
132	NAFLD Induction Delays Postoperative Liver Regeneration of ALPPS in Rats. Digestive Diseases and Sciences, 2019, 64, 456-468.	1.1	12
133	Adult Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 23-46.		0
134	Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis. Magnetic Resonance Imaging, 2019, 57, 210-217.	1.0	11
135	High dietary intake of palm oils compromises glucose tolerance whereas high dietary intake of olive oil compromises liver lipid metabolism and integrity. European Journal of Nutrition, 2019, 58, 3091-3107.	1.8	12
136	Perioperative and prognostic implication of albuminâ€bilirubinâ€‹scp›TNM‹/scp› score in Childâ€Pugh class A hepatocellular carcinoma. Annals of Gastroenterological Surgery, 2019, 3, 65-74.	1.2	12
137	Night shift work and abnormal liver function: is non-alcohol fatty liver a necessary mediator?. Occupational and Environmental Medicine, 2019, 76, 83-89.	1.3	30
138	Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2019, 64, 1238-1256.	1.1	15
139	Reproductive Endocrinology of Nonalcoholic Fatty Liver Disease. Endocrine Reviews, 2019, 40, 417-446.	8.9	73
140	Adipose may actively delay progression of NAFLD by releasing tumorâ€suppressing, antiâ€fibrotic miR â€122 into circulation. Obesity Reviews, 2019, 20, 108-118.	3.1	35
141	Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial. Nutrition, 2019, 57, 154-161.	1.1	54
142	Prediction of Liver Steatosis Applying a New Score in Subjects from the Brazilian Longitudinal Study of Adult Health. Journal of Clinical Gastroenterology, 2020, 54, e1-e10.	1.1	7
143	Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. British Journal of Nutrition, 2020, 123, 190-197.	1.2	16
144	The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. Annals of Hepatology, 2020, 19, 44-52.	0.6	27
145	Development and Validation of Hepamet Fibrosis Scoring Systemâ€“A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2020, 18, 216-225.e5.	2.4	104

#	Article	IF	Citations
146	Electroacupuncture Versus Aerobic Interval Training on Liver Functions in Patients with Nonalcoholic Fatty Liver. Journal of Alternative and Complementary Medicine, 2020, 26, 51-57.	2.1	17
147	Anatomical Configuration of the Stomach Post-Endoscopic Sleeve Gastroplasty (ESG)â€"What Are the Sutures Doing?. Obesity Surgery, 2020, 30, 2056-2060.	1.1	10
148	Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomedicine and Pharmacotherapy, 2020, 123, 109721.	2.5	32
149	Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. Journal of Diabetes and Its Complications, 2020, 34, 107512.	1.2	11
150	Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches. Digestive Diseases, 2020, 38, 269-279.	0.8	15
151	Functional Genomics Identifies Hepatitis-Induced STAT3â€"TYRO3â€"STAT3 Signaling as a Potential Therapeutic Target of Hepatoma. Clinical Cancer Research, 2020, 26, 1185-1197.	3.2	12
152	Liver disease: changing epidemiology. British Journal of Health Care Management, 2020, 26, 84-86.	0.1	0
153	Effects of sodiumâ€glucose coâ€transporter 2 inhibitors on liver parameters and steatosis: A metaâ€analysis of randomized clinical trials. Diabetes/Metabolism Research and Reviews, 2021, 37, e3413.	1.7	32
154	The isonicotinamide cocrystal promotes inhibitory effects of naringenin on nonalcoholic fatty liver disease in mice. Journal of Drug Delivery Science and Technology, 2020, 59, 101874.	1.4	4
155	Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. Frontiers in Nutrition, 2020, 7, 593735.	1.6	46
156	Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment. Frontiers in Immunology, 2020, 11, 574276.	2.2	73
157	Hepatic KrÃ¼ppel-like factor 16 (KLF16) targets PPARÎ± to improve steatohepatitis and insulin resistance. Gut, 2021, 70, 2183-2195.	6.1	54
158	9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes. International Journal of Molecular Sciences, 2020, 21, 8279.	1.8	11
159	Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy. Surgery for Obesity and Related Diseases, 2020, 16, 2050-2057.	1.0	20
160	Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Japanese Journal of Clinical Oncology, 2020, 50, 1370-1379.	0.6	42
161	Ginsenoside Rb1 Alleviated High-Fat-Diet-Induced Hepatocytic Apoptosis via Peroxisome Proliferator-Activated Receptor Î³. BioMed Research International, 2020, 2020, 1-9.	0.9	12
162	Generation of sphingosine-1-phosphate by sphingosine kinase 1 protects nonalcoholic fatty liver from ischemia/reperfusion injury through alleviating reactive oxygen species production in hepatocytes. Free Radical Biology and Medicine, 2020, 159, 136-149.	1.3	10
163	Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Medicine (United States), 2020, 99, e21568.	0.4	3

#	Article	IF	Citations
164	Regulatory Connections between Iron and Glucose Metabolism. International Journal of Molecular Sciences, 2020, 21, 7773.	1.8	26
165	Liver Steatosis Categorization on Contrast-Enhanced CT Using a Fully Automated Deep Learning Volumetric Segmentation Tool: Evaluation in 1204 Healthy Adults Using Unenhanced CT as a Reference Standard. American Journal of Roentgenology, 2021, 217, 359-367.	1.0	31
166	Early Life Exposure to Nicotine: Postnatal Metabolic, Neurobehavioral andÂRespiratory Outcomes and the Development of Childhood Cancers. Toxicological Sciences, 2020, 178, 3-15.	1.4	18
167	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Diabetes Research, 2020, 2020, 1-16.	1.0	196
168	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. Liver International, 2020, 40, 3061-3070.	1.9	13
169	Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Disease Markers, 2020, 2020, 1-16.	0.6	26
170	Current and Emerging Treatments for Non-alcoholic Steatohepatitis. Current Hepatology Reports, 2020, 19, 391-401.	0.4	2
171	Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. Medicine (United States), 2020, 99, e21463.	0.4	3
172	Cytokinesâ€™ Involvement in Periodontal Changes. , 0, , .		0
173	A simple, rapid, interpretable, actionable and implementable digital PCR based mortality index. Epigenetics, 2020, 16, 1-15.	1.3	2
174	Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Medicine, 2020, 9, 3522.	1.0	8
175	The Role of the Histone Methyltransferase EZH2 in Liver Inflammation and Fibrosis in STAM NASH Mice. Biology, 2020, 9, 93.	1.3	13
176	Disruption of hepatic one-carbon metabolism impairs mitochondrial function and enhances macrophage activity in methionineâ€“choline-deficient mice. Journal of Nutritional Biochemistry, 2020, 81, 108381.	1.9	3
177	Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease. Medicine (United States), 2020, 99, e20624.	0.4	0
178	Bacterial antigen translocation and age as BMIâ€independent contributing factors on systemic inflammation in NAFLD patients. Liver International, 2020, 40, 2182-2193.	1.9	14
179	Relationship between hepatic and systemic angiopoietinâ€like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver International, 2020, 40, 2139-2147.	1.9	25
180	Utilization of a Deep Learning Algorithm for Microscope-Based Fatty Vacuole Quantification in a Fatty Liver Model in Mice. Toxicologic Pathology, 2020, 48, 702-707.	0.9	26
181	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	3.9	47

#	Article	IF	Citations
182	Long-term environmental exposure to microcystins increases the risk of nonalcoholic fatty liver disease in humans: A combined fisher-based investigation and murine model study. Environment International, 2020, 138, 105648.	4.8	46
183	MiR-149 attenuates endoplasmic reticulum stress-induced inflammation and apoptosis in nonalcoholic fatty liver disease by negatively targeting ATF6 pathway. Immunology Letters, 2020, 222, 40-48.	1.1	42
184	The significance of IL-28B and CK-18 M30 levels in the diagnosis of non-alcoholic steatohepatitis in SD rats. Pathology Research and Practice, 2020, 216, 152901.	1.0	6
185	Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. Journal of Translational Medicine, 2020, 18, 133.	1.8	22
186	Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-Î±, UCP1, and UCP2 genes. Pharmacological Research, 2020, 156, 104770.	3.1	37
187	Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Archives of Physiology and Biochemistry, 2020, , 1-15.	1.0	9
188	Nonalcoholic fatty liver disease, insulin resistance, and sweeteners: a literature review. Expert Review of Endocrinology and Metabolism, 2020, 15, 83-93.	1.2	15
189	Corilagin Alleviates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced C57BL/6 Mice by Ameliorating Oxidative Stress and Restoring Autophagic Flux. Frontiers in Pharmacology, 2019, 10, 1693.	1.6	35
190	Lycium ruthenicum Murr. alleviates nonalcoholic fatty liver in mice. Food Science and Nutrition, 2020, 8, 2588-2597.	1.5	8
191	Risk Prediction for Non-alcoholic Fatty Liver Disease Based on Biochemical and Dietary Variables in a Chinese Han Population. Frontiers in Public Health, 2020, 8, 220.	1.3	11
192	Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease. Medicine (United States), 2020, 99, e20695.	0.4	0
193	Protein acetylation in mitochondria plays critical functions in the pathogenesis of fatty liver disease. BMC Genomics, 2020, 21, 435.	1.2	24
194	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Medicine, 2020, 8, 205031212093380.	0.7	12
195	RNA N6-methyladenosine: a promising molecular target in metabolic diseases. Cell and Bioscience, 2020, 10, 19.	2.1	29
196	A Rare Mutation in The APOB Gene Associated with Neurological Manifestations in Familial Hypobetalipoproteinemia. International Journal of Molecular Sciences, 2020, 21, 1439.	1.8	7
197	One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All. Journal of Nutrition, 2020, 150, 994-1003.	1.3	31
198	Computed Tomography Measurements of Hepatic Steatosis in Cholelitihiasis and Cholecystectomy Cases Using Unenhanced Images. Journal of Medical Imaging and Radiation Sciences, 2020, 51, 137-144.	0.2	1
199	Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver International, 2020, 40, 1098-1110.	1.9	21

#	Article	IF	Citations
200	Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD. Nutrients, 2020, 12, 270.	1.7	7
201	Maternal exposure to air pollution during pregnancy and cortisol level in cord blood. Science of the Total Environment, 2020, 713, 136622.	3.9	24
202	Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. PLoS ONE, 2020, 15, e0228212.	1.1	25
203	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-10.	0.8	40
204	Epidemiology, risk factors across the spectrum of age-related metabolic diseases. Journal of Trace Elements in Medicine and Biology, 2020, 61, 126497.	1.5	10
205	Identification of Crucial Genetic Factors, Such as PPARÎ³, that Regulate the Pathogenesis of Fatty Liver Disease in Dairy Cows Is Imperative for the Sustainable Development of Dairy Industry. Animals, 2020, 10, 639.	1.0	16
206	Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS ONE, 2020, 15, e0231196.	1.1	23
207	Efficacy of Hijamat (wet cupping therapy) in Iranian patients with nonalcoholic fatty liver disease: a controlled clinical trial. Turkish Journal of Medical Sciences, 2020, 44, 354-359.	0.4	9
208	Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes/Metabolism Research and Reviews, 2021, 37, e3358.	1.7	27
209	Patientâ€reported outcomes in patients with nonâ€alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaireâ€nonâ€alcoholic fatty liver disease/nonâ€alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 629-636.	1.4	22
210	Freeâ€breathing liver fat and quantification using motionâ€corrected averaging based on a nonlocal means algorithm. Magnetic Resonance in Medicine, 2021, 85, 653-666.	1.9	2
211	Cafeteria diet from birth to adulthood promotes hepatic steatosis and redox imbalance in Wistar rats. Nutrition and Food Science, 2021, 51, 483-493.	0.4	1
212	Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway. Pharmacological Research, 2021, 163, 105298.	3.1	9
213	Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101568.	0.7	6
214	Association between periodontitis and fibrotic progression of nonâ€alcoholic fatty liver among Japanese adults. Journal of Clinical Periodontology, 2021, 48, 368-377.	2.3	13
215	Liver complications of haemoglobin H disease in adults. British Journal of Haematology, 2021, 192, 171-178.	1.2	3
216	Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with nonâ€alcoholic fatty liver disease: A doubleâ€blind randomized controlled clinical trial. Phytotherapy Research, 2021, 35, 477-485.	2.8	10
217	The role of TLR4/MyD88/NFâ€ÎºB pathway in periodontitisâ€induced liver inflammation of rats. Oral Diseases, 2021, 27, 1012-1021.	1.5	18

#	Article	IF	Citations
218	Composite BMI and Waist-to-Height Ratio Index for Risk Assessment of Non-alcoholic Fatty Liver Disease in Adult Populations. Hepatitis Monthly, 2021, 20, .	0.1	2
219	Effectiveness of dietary interventions on cardio-metabolic risk factors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Annals of Gastroenterology, 2021, 34, 415-423.	0.4	0
220	Mitochondrial role in NAFLD as a chronic disease. , 2021, , 155-167.		0
221	Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population. International Journal of Environmental Research and Public Health, 2021, 18, 857.	1.2	32
222	Efeitos Nutricionais e Mecanismos BioquÃmicos na DoenÃ§a HepÃ¡tica Gordurosa NÃ£o AlcoÃ³lica. Revista Da AssociaÃ§Ã£o Brasileira De NutriÃ§Ã£o, 2021, 12, 195-214.	0.1	0
223	Resveratrol reverses the programmed high-susceptibility to non-alcoholic fatty liver disease by targeting the hepatic SIRT1-SREBP1c pathway in prenatal ethanol-exposed rat offspring. Journal of Toxicological Sciences, 2021, 46, 413-423.	0.7	3
224	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines, 2021, 9, 60.	1.4	37
225	In Vitro Antioxidant Activities and the Therapeutic Potential of Some Newly Synthesized Chalcones Against 4-Acetaminophenol Induced Hepatotoxicity in Rats. Dose-Response, 2021, 19, 155932582199695.	0.7	5
226	Increase of Î±-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. OncoImmunology, 2021, 10, 1874159.	2.1	9
227	Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress. Free Radical Biology and Medicine, 2021, 164, 1-12.	1.3	19
228	The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease. International Journal of Molecular Sciences, 2021, 22, 1593.	1.8	73
229	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2021, 31, 2002-2010.	1.1	14
231	The beneficial effects of taurine in alleviating fatty liver disease. Journal of Functional Foods, 2021, 77, 104351.	1.6	15
232	FGF-21 LEVELS AND LIVER INFLAMMATORY BIOMARKERS IN OBESE SUBJECTS AFTER WEIGHT LOSS.. Archives of Medical Science, 2021, 18, 36-44.	0.4	3
233	Inhibition of preadipocyte differentiation by Lycium barbarum polysaccharide treatment in 3T3-L1 cultures. Electronic Journal of Biotechnology, 2021, 50, 53-58.	1.2	5
234	Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. Archives of Physiology and Biochemistry, 2023, 129, 975-983.	1.0	16
235	Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 1167-1175.	1.1	5
236	Insights into Macrophage/Monocyte-Endothelial Cell Crosstalk in the Liver: A Role for Trem-2. Journal of Clinical Medicine, 2021, 10, 1248.	1.0	7

#	Article	IF	Citations
237	SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction. Frontiers in Endocrinology, 2021, 12, 641446.	1.5	14
238	High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. Microorganisms, 2021, 9, 968.	1.6	5
239	ÐšÐ›Ð†ÐÐ†ÐšÐž-Ð›ÐÐ‘ÐžÐÐ¢ÐžÐÐÐ† ÐŸÐžÐšÐÐ—ÐÐ˜ÐšÐ˜ Ð£ ÐŸÐÐ¦Ð†Ð„ÐÐ¢Ð’ Ð— ÐÐ•ÐÐ›ÐšÐžÐ‘Ð›ÐÐ®Ð®Ð®Ð–Ð—Ð˜ÐÐžÐ		
240	TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis. Lipids in Health and Disease, 2021, 20, 39.	1.2	5
241	Protective Effect of Cudrania tricuspidata Extract against High-Fat Diet Induced Nonalcoholic Fatty Liver Disease through Nrf-2/HO-1 Pathway. Molecules, 2021, 26, 2434.	1.7	5
242	Non-alcoholic fatty liver diseases: current challenges and future directions. Annals of Translational Medicine, 2021, 9, 726-726.	0.7	16
243	Fatty Liver Disease Prediction Model Based on Big Data of Electronic Physical Examination Records. Frontiers in Public Health, 2021, 9, 668351.	1.3	5
244	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Advances in Therapy, 2021, 38, 2130-2158.	1.3	46
245	Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLrâ^'/â^'.Leiden mice without attenuation of steatohepatitis. Scientific Reports, 2021, 11, 8250.	1.6	14
246	Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2022, 20, 740-755.	2.4	19
247	Parthenolide plays a protective role in the liver of mice with metabolic dysfunctionâ€‘associated fatty liver disease through the activation of the HIPPO pathway. Molecular Medicine Reports, 2021, 24, .	1.1	8
248	Calcium transfer between endoplasmic reticulum and mitochondria in liver diseases. FEBS Letters, 2021, 595, 1411-1421.	1.3	13
249	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. International Journal of Molecular Sciences, 2021, 22, 4495.	1.8	56
250	Melatonin Levels in Patients with Nonalcoholic Fatty Liver Disease Compared with Healthy Individuals according to Fibrosis Level. Middle East Journal of Digestive Diseases, 2021, 13, 109-114.	0.2	3
251	Dietary fructose as a model to explore the influence of peripheral metabolism on brain function and plasticity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166036.	1.8	8
252	Estrogen Receptor-Î± Suppresses Liver Carcinogenesis and Establishes Sex-Specific Gene Expression. Cancers, 2021, 13, 2355.	1.7	19
253	Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?. Journal of Pathology, 2021, 254, 216-228.	2.1	30
254	Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice. Journal of Nutritional Biochemistry, 2021, 91, 108602.	1.9	24

#	Article	IF	Citations
255	Hyperoside attenuates non-alcoholic fatty liver disease through targeting Nr4A1 in macrophages. International Immunopharmacology, 2021, 94, 107438.	1.7	22
256	The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes. Diabetes Care, 2021, 44, 1706-1713.	4.3	11
257	Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs and Therapy Perspectives, 2021, 37, 249-264.	0.3	5
258	Liver-Related and Cardiovascular Outcome of Patients Transplanted for Nonalcoholic Fatty Liver Disease: A European Single-Center Study. Transplantation Proceedings, 2021, 53, 1674-1681.	0.3	5
259	Hepatocrinology. Medical Sciences (Basel, Switzerland), 2021, 9, 39.	1.3	1
260	Non-Alcoholic Fatty Liver Disease: Implementing Complete Automated Diagnosis and Staging. A Systematic Review. Diagnostics, 2021, 11, 1078.	1.3	13
261	TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. Journal of Clinical Medicine, 2021, 10, 2907.	1.0	12
262	The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. Journal of Basic and Clinical Physiology and Pharmacology, 2021, 32, 637-644.	0.7	11
263	A PRISMA-compliant meta-analysis of apolipoprotein C3 polymorphisms and non-alcoholic fatty liver disease. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, 923-929.	0.6	4
264	Fructose and the Liver. International Journal of Molecular Sciences, 2021, 22, 6969.	1.8	56
265	Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression. Molecular Metabolism, 2021, 48, 101210.	3.0	20
266	Application of ischaemiaâ€free liver transplantation improves prognosis of patients with steatotic donor livers â€“ a retrospective study. Transplant International, 2021, 34, 1261-1270.	0.8	6
267	Ultrasound-Based Quantification of Fibrosis and Steatosis with a New Software Considering Transient Elastography as Reference in Patients with Chronic Liver Diseases. Ultrasound in Medicine and Biology, 2021, 47, 1692-1703.	0.7	15
268	A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells, 2021, 10, 1822.	1.8	24
269	Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United Statesâ€™ adolescent population. World Journal of Hepatology, 2021, 13, 790-803.	0.8	1
270	Fatty Liver Is an Independent Risk Factor for Delayed Recovery from Anesthesia. Hepatology Communications, 2021, 5, 1848-1859.	2.0	2
271	Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study. Journal of Clinical and Translational Hepatology, 2022, 10, 6-16.	0.7	27
272	Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. Indian Journal of Gastroenterology, 2021, 40, 380-388.	0.7	8

#	Article	IF	Citations
273	Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH. International Journal of Molecular Sciences, 2021, 22, 8489.	1.8	8
274	Thiazolidinediones and Glucagonâ€Like Peptideâ€1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology, 2021, 74, 2467-2477.	3.6	10
275	Antifibrotic Effects of Kangxian Ruangan Capsule on Rats with Nonalcoholic Fatty Liver Fibrosis and Hepatic Stellate Cells through Regulation of TGF-Î² and TLR4 Signaling Pathways. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14.	0.5	2
276	A qualitative study of selfâ€management experiences in people with nonâ€alcoholic fatty liver disease. Nursing Open, 2021, 8, 3135-3142.	1.1	9
277	Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease. Canadian Liver Journal, 2021, 4, 275-282.	0.3	2
278	Fatty liver index and progression to type 2 diabetes: a 5-year longitudinal study in Spanish workers with pre-diabetes. BMJ Open, 2021, 11, e045498.	0.8	12
279	The â€œGGâ€•genotype of rs26802 variant in the ghrelin gene is a potential protective factor against nonalcoholic fatty liver disease. Physiology International, 2021, 108, 342-352.	0.8	2
280	Consumption of processed red meat and its impact on human health: A review. International Journal of Food Science and Technology, 2021, 56, 6115-6123.	1.3	24
281	Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism. BMJ Case Reports, 2021, 14, e244805.	0.2	0
282	Proteome analysis identified proteins associated with mitochondrial function and inflammation activation crucially regulating the pathogenesis of fatty liver disease. BMC Genomics, 2021, 22, 640.	1.2	3
283	Ameliorative role of ellagic acid against acute liver steatosis in adult zebrafish experimental model. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2021, 247, 109061.	1.3	2
284	Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis. Nutrients, 2021, 13, 3370.	1.7	8
285	Modeling PNPLA3â€Associated NAFLD Using Humanâ€Induced Pluripotent Stem Cells. Hepatology, 2021, 74, 2998-3017.	3.6	35
286	Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e745-e755.	1.8	40
287	Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Medicine, 2021, 10, 7308-7319.	1.3	6
288	Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases. Diabetes and Metabolism Journal, 2021, 45, 655-674.	1.8	8
289	A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease. Current Opinion in Pharmacology, 2021, 60, 281-290.	1.7	4
290	Glycogenic hepatopathy in children with poorly controlled type 1 diabetes mellitus. Clinical Pediatric Endocrinology, 2021, 30, 93-97.	0.4	3

#	Article	IF	Citations
291	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1703-1713.	1.4	12
292	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunological Medicine, 2021, 44, 175-186.	1.4	5
293	Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Translational Gastroenterology and Hepatology, 2021, 6, 3-3.	1.5	21
294	Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. International Journal of Molecular Sciences, 2021, 22, 436.	1.8	40
295	NAFLD as a driver of chronic kidney disease. Journal of Hepatology, 2020, 72, 785-801.	1.8	249
296	Etiological factors of chronic hepatitis in Italy. European Journal of Gastroenterology and Hepatology, 2017, 29, 994-997.	0.8	5
297	Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. European Journal of Gastroenterology and Hepatology, 2021, 33, 1298-1306.	0.8	14
300	Goat Milk Whey Improves Nutritional Status, Fecal Microbial Composition and Intestinal Morphology in Female Rats Fed a Westernized Diet and Their Offspring. Journal of Food and Nutrition Research (Newark, Del), 2019, 7, 291-302.	0.1	2
301	Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World Journal of Clinical Cases, 2019, 7, 2269-22286.	0.3	21
302	Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World Journal of Clinical Cases, 2020, 8, 5235-5249.	0.3	20
303	Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2018, 110, 634-640.	0.1	12
304	The Prevalence and Predictors of Non-alcoholic Fatty Liver Disease in Morbidly Obese Women â€“ A Cross-sectional Study from Southern India. European Endocrinology, 2020, 16, 152.	0.8	22
305	Collagen I promotes hepatocellular carcinoma cell proliferation by regulating integrin Î²1/FAK signaling pathway in nonalcoholic fatty liver. Oncotarget, 2017, 8, 95586-95595.	0.8	37
306	Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Current Medicinal Chemistry, 2020, 27, 3290-3301.	1.2	5
307	A Case Report of Nonalcoholic Steatohepatitis with Metabolic Syndrome. The Journal of Internal Korean Medicine, 2017, 38, 125-130.	0.0	4
308	Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Terapevticheskii Arkhiv, 2019, 91, 143-148.	0.2	8
309	High oleic peanuts improve parameters leading to fatty liver development and change the microbiota in mice intestine. Food and Nutrition Research, 2020, 64, .	1.2	8
310	Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study). Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 4-10.	0.1	1

#	Article	IF	Citations
311	Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2018, 24, 1239-1249.	1.4	39
312	Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we. World Journal of Gastroenterology, 2019, 25, 3842-3848.	1.4	9
313	Management of nonalcoholic fatty liver disease in the Middle East. World Journal of Gastroenterology, 2020, 26, 3528-3541.	1.4	14
314	Clinicopathologic characteristics and outcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection. Annals of Saudi Medicine, 2018, 38, 358-365.	0.5	5
315	Effect of an Herbal Product on the Serum Level of Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial. Iranian Red Crescent Medical Journal, 2019, 21, .	0.5	5
316	Risk Factors for Non-alcoholic Fatty Liver Disease in Chinese Population: A Five-year Follow-up Study. Iranian Red Crescent Medical Journal, 2019, 21, .	0.5	2
317	Fatty liver is a risk factor for liver metastasis in Chinese patients with non-small cell lung cancer. PeerJ, 2019, 7, e6612.	0.9	13
318	Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World Journal of Hepatology, 2021, 13, 1203-1207.	0.8	2
320	Recurrent NASH Post-liver Transplant: Implications and Treatment. Current Hepatology Reports, 2021, 20, 108.	0.4	0
321	Sarcopenia in Non-alcoholic Steatohepatitis (NASH). Current Hepatology Reports, 0, , 1.	0.4	0
322	Investigation of Fatty Liver and Cardiovascular Risk Factors on Civil Servantsâ€™ of a Town in Beijing Daxing District. Ya Zhou Xin Nao Xue Guan Bing Li Bao Gao, 2017, 05, 15-22.	0.3	0
323	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. Open Hypertension Journal, 2017, 9, 1-5.	0.8	0
324	Effect of Soybean (glycine max) Leaf Extract against the Development of Non-alcoholic Fatty Liver in High Fat Diet-fed Mice. Journal of the Pharmaceutical Society of Korea, 2017, 61, 195-202.	0.1	3
325	Diagnostic Approach. Clinical Gastroenterology, 2018, , 317-327.	0.0	0
328	COMORBIDITY SEVERITY INDEX AS A NEW TOOL FOR ASSESSMENT OF CO-EXISTING DISEASES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AT THE CARBOHYDRATE METABOLISM DISORDER BACKGROUND AND CONCOMITANT SUBCLINICAL HYPOTHYROIDISM. WiadomoÅ›ci Lekarskie, 2019, 72, 650-653.	0.1	0
329	High-dose Î²-carotene exacerbates high-fat/high-sucrose diet-inducible fibrosis in the liver of Mongolian gerbils. Fundamental Toxicological Sciences, 2019, 6, 235-243.	0.2	0
330	Chronic Hepatitis. , 2019, , 51-60.		0
331	The Effect of a Conventional Resistance Training Course on Some of the Inflammatory Factors in Obese Men with Non-Alcoholic Fatty Liver. Jundishapur Journal of Chronic Disease Care, 2019, In Press, .	0.1	0

#	Article	IF	Citations
332	Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. Russian Journal of Gastroenterology Hepatology Coloproctology, 2019, 29, 17-23.	0.2	3
333	Diallyl disulfide attenuates nonâ€'alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, lipid peroxidation and inflammation in mice. Molecular Medicine Reports, 2019, 20, 1363-1372.	1.1	9
335	Regression of Nonalcoholic Fatty Liver Disease Detected by Sonography: Results of a Four Years Prospective Adult Population-based Study. Hepatitis Monthly, 2019, In Press, .	0.1	0
336	Assessment Of Fetuin-A In Patients With Comorbidity Of Non-Alcoholic Fatty Liver Disease And Arterial Hypertension. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2019, 2019, 83-89.	0.0	0
337	Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model. Journal of Clinical Biochemistry and Nutrition, 2020, 67, 274-282.	0.6	3
338	A Retrospective Population Study to Develop a Predictive Model of Prediabetes and Incident Type 2 Diabetes Mellitus from a Hospital Database in Japan Between 2004 and 2015. Medical Science Monitor, 2020, 26, e920880.	0.5	3
339	Changes in indicators of fibrosis in patients with alcoholic liver cirrhosis associated with non-alcoholic fatty liver disease depending on the stage of cirrhosis. PatologÃ¤, 2020, .	0.1	0
340	Toward Quantitative and Operator-independent Quasi-static Ultrasound Elastography: An Ex Vivo Feasibility Study. Ultrasonic Imaging, 2020, 42, 179-190.	1.4	3
341	Non-alcoholic fatty liver disease: modern methods of diagnostics and treatment strategies. Modern Gastroenterology, 2020, .	0.1	1
342	â€œHepatogenic diabetesâ€•is an old term and new meaning. Meditsinskiy Sovet, 2020, , 19-24.	0.1	0
343	Covid-19 infection, liver injury and prognosis: a suggestion. European Journal of Gastroenterology and Hepatology, 2021, 33, 451-452.	0.8	4
344	Association of vitamin D supplementation with serum leptin and metabolic parameters in Egyptian patients with non-alcoholic steatohepatitis: a prospective study. Egyptian Liver Journal, 2020, 10, .	0.3	2
345	Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 396-403.	0.1	0
346	Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-3.	0.8	4
347	Does Hepatic Steatosis Influence the Detection Rate of Metastases in the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI?. Journal of Clinical Medicine, 2021, 10, 98.	1.0	0
348	Non-alcoholic fatty liver disease: non-invasive markers and their importance in diagnosis. Modern Gastroenterology, 2020, .	0.1	0
349	Effect of Circuit Resistance Training and L-Carnitine Supplementation on Body Composition and Liver Function in Men with Non-Alcoholic Fatty Liver Disease. Jundishapur Journal of Chronic Disease Care, 2019, 8, .	0.1	1
350	An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis. Methods in Molecular Biology, 2020, 2164, 121-127.	0.4	0

#	Article	IF	Citations
352	MR spectroscopy of the liver â€“ a reliable non-invasive alternative for evaluating non-alcoholic fatty liver disease. Romanian Journal of Morphology and Embryology, 2020, 61, 73-80.	0.4	1
354	Kupffer Cell Isolation from Human Biopsies. Methods in Molecular Biology, 2020, 2164, 11-13.	0.4	0
355	Dietary Approach to NAFLD. , 2020, , 271-287.		1
356	Comparative evaluation of variants of comorbidity of the non-alcoholic fatty liver disease with arterial hypertension according to multivariate analysis. Modern Gastroenterology, 2020, .	0.1	0
358	CHANGES IN FIBROSIS UNDER THE INFLUENCE OF TREATMENT OF PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER IN COMBINATION WITH OBESITY USING ADEMETHYANINIUM AND ARGININE GLUTAMATE. , 2020, 3, 27-34.	0.3	0
359	Pituitary stalk interruption syndrome and liver changes: From clinical features to mechanisms. World Journal of Gastroenterology, 2020, 26, 6909-6922.	1.4	5
360	Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. BMJ Open Gastroenterology, 2018, 5, e000150.	1.1	6
361	Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. Journal of Medicine and Life, 2018, 11, 20-23.	0.4	27
362	Before and After Treatment Quantitative Assessment of Hepatic Steatosis in a Romanian Population Using Magnetic Resonance Liver Spectroscopy. Current Health Sciences Journal, 2019, 45, 258-262.	0.2	0
363	miR-122-5p/KIF5B/AMPK/AKT regulatory network regulates the progression of NAFLD. American Journal of Translational Research (discontinued), 2021, 13, 696-707.	0.0	0
364	Is melatonin associated with pro-inflammatory cytokine activity and liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients?. Gastroenterology and Hepatology From Bed To Bench, 2021, 14, 229-236.	0.6	0
366	(+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARÎ±â€“FGF21 Pathway. Frontiers in Pharmacology, 2021, 12, 750147.	1.6	8
367	Causal effects from nonâ€alcoholic fatty liver disease on kidney function: A Mendelian randomization study. Liver International, 2022, 42, 412-418.	1.9	11
368	Targeted Metabolomics Profiles Serum Fatty Acids by HFD Induced Non-Alcoholic Fatty Liver in Mice Based on GC-MS. SSRN Electronic Journal, 0, , .	0.4	0
369	Nonalcoholic fatty liver disease among long-term hospitalized patients with schizophrenia in a public psychiatric hospital. Taiwanese Journal of Psychiatry, 2021, 35, 197.	0.1	1
370	Adiponectin alleviates nonalcoholic fatty liver injury via regulating oxidative stress in liver cells. Minerva Medica, 2020, , .	0.3	2
371	Investigation of the Effect of Artichoke (Cynara Scolymus L.) on Characteristics of the Fatty Liver. Complementary Medicine Journal of Faculty of Nursing and Midwifery, 2020, 10, 134-147.	0.3	1
372	An algorithm for the management of non-alcoholic fatty liver disease in primary care. Gastroenterology & Hepatology (Bartlesville, Okla), 2021, 12, 114-122.	0.0	0

#	Article	IF	Citations
373	Targeted metabolomics profiles serum fatty acids by HFD induced non-alcoholic fatty liver in mice based on GC-MS. Journal of Pharmaceutical and Biomedical Analysis, 2022, 211, 114620.	1.4	10
374	Sitagliptin Is More Effective Than Gliclazide in Preventing ÂPro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. Molecules, 2022, 27, 727.	1.7	7
375	MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Frontiers in Medicine, 2021, 8, 774079.	1.2	15
376	Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques. Korean Journal of Radiology, 2022, 23, 13.	1.5	18
377	Identification of liver disease: why and how. Frontline Gastroenterology, 2022, 13, 367-373.	0.9	12
378	Search for a way to improve the serum albumin binding function and the functional state of the liver when hypertension combined with non-alcoholic fatty liver disease. Journal of Education, Health and Sport, 2021, 12, 55-64.	0.0	0
379	ASSOCIATION OF SONOGRAPHIC GRADING OF FATTY LIVER DISEASE WITH LIVER FUNCTION TESTS AND CT HOUNSFIELD. Pakistan Biomedical Journal, 2021, 5, .	0.0	0
380	Hipogonad erkeklerde non-alkolik yaÄŸlÄ± karaciÄŸer hastalÄ±ÄŸÄ± ve fibroscan verileri. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.1	0
381	Ameliorating effects of water bamboo shoot (Zizania latifolia) on acute alcoholism in a mice model and its chemical composition. Food Chemistry, 2022, 378, 132122.	4.2	16
382	Blockage of NDUFB9-SCD1 pathway inhibits adipogenesis. Journal of Physiology and Biochemistry, 2022, 78, 377-388.	1.3	6
383	Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia, 2022, 65, 518-527.	2.9	12
384	Risk factors and pathogenic mechanismâ€“associated hepatocellular carcinoma. , 2022, , 33-49.		0
385	Increased brain-derived neurotrophic factor in the serum of persons with nonalcoholic fatty liver disease. Endocrine Journal, 2022, , .	0.7	2
387	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv, 2022, 94, 216-253.	0.2	19
388	Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	5
389	The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. Metabolites, 2022, 12, 215.	1.3	10
390	Tissue-Dependent Adaptations and Functions of Innate Lymphoid Cells. Frontiers in Immunology, 2022, 13, 836999.	2.2	18
391	Awareness of Augmentative and Alternative Communication among Final Semester Students of SLP. Pakistan Biomedical Journal, 0, , .	0.0	0

#	Article	IF	Citations
392	Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells. Cells, 2022, 11, 1067.	1.8	4
393	Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metabolism, 2022, 34, 719-730.e4.	7.2	35
394	Epigenetic remodelling in human hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 107.	3.5	21
395	Correlation of Adiponectin Gene Polymorphisms rs266729 and rs3774261 With Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2022, 13, 798417.	1.5	2
396	Hepatic Epigenetic Reprogramming After Liver Resection in Offspring Alleviates the Effects of Maternal Obesity. Frontiers in Cell and Developmental Biology, 2022, 10, 830009.	1.8	2
397	Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. Diabetes and Metabolism, 2022, 48, 101344.	1.4	15
398	PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opinion on Therapeutic Targets, 2021, 25, 1033-1043.	1.5	22
399	Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study. BMJ Open, 2021, 11, e056260.	0.8	8
400	The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. Biomedicines, 2021, 9, 1853.	1.4	12
401	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approachâ€"the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine, 2022, 2, 12-22.	0.1	2
402	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Frontiers in Endocrinology, 2021, 12, 768850.	1.5	11
413	Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. BMJ Open Gastroenterology, 2018, 5, e000150.	1.1	9
415	A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-15.	1.9	17
416	Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. Journal of Clinical Medicine, 2022, 11, 2759.	1.0	4
417	Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague–Dawley rats fed a high-cholesterol diet. Inflammation Research, 2022, , .	1.6	0
418	Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition. Current Nutrition and Food Science, 2022, 18, .	0.3	0
419	TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Molecular Neurodegeneration, 2022, 17, .	4.4	36
420	Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study. Diabetes and Metabolism, 2022, 48, 101362.	1.4	3

#	Article	IF	Citations
422	Citrus maxima and tea regulate AMPK signaling pathway to retard the progress of nonalcoholic fatty liver disease. Food and Nutrition Research, 0, 66, .	1.2	3
423	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. Schizophrenia Research, 2022, 246, 30-38.	1.1	3
424	Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	1
425	Dietary Acid Load (DAL), Glycated Hemoglobin A1c (HbA1c), and Metabolic Syndrome (MeS) Mediate the Association of the Adherence to the Dietary Approaches to Stopping Hypertension (DASH) and Mediterranean Diet (MeD) With Nonalcoholic Fatty Liver Disease. Frontiers in Nutrition, 0, 9, .	1.6	3
426	Wheat germ improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placeboâ€controlled, doubleâ€blind clinical trial. Phytotherapy Research, 2022, 36, 4201-4209.	2.8	3
427	Distinct impacts of fat and fructose on the liver, muscle, and adipose tissue metabolome: An integrated view. Frontiers in Endocrinology, 0, 13, .	1.5	2
428	A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity. Metabolites, 2022, 12, 732.	1.3	6
429	Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial Based on the Theory of Planned Behavior. BioMed Research International, 2022, 2022, 1-10.	0.9	9
430	The effects of seaweed supplementation consumption for improvement of liver injury in patients with non-alcoholic fatty liver disease: a systematic review. Clinical and Experimental Hepatology, 2022, 8, 171-177.	0.6	1
431	Biomarkers in Liver Disease. , 2022, , 490-521.		0
432	Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase. International Journal of Molecular Sciences, 2022, 23, 10072.	1.8	1
433	Resveratrol Attenuates Non-alcoholic Fatty Liver Disease in Obese Mice Modulating MAF1. Revista Brasileira De Farmacognosia, 2022, 32, 786-795.	0.6	2
434	Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice. Ultrasound, 0, , 1742271X2211225.	0.3	1
435	Fatty liver disease in overweight and obese Iranian Children: Comprehensive systematic review and meta-analysis. Obesity Medicine, 2022, 35, 100455.	0.5	1
436	Advances in Anti-metabolic Disease Treatments Targeting CD47. Current Pharmaceutical Design, 2022, 28, 3720-3728.	0.9	1
437	Fatty Acids and Eicosanoids Change during High-Fiber Diet in NAFLD Patientsâ€"Randomized Control Trials (RCT). Nutrients, 2022, 14, 4310.	1.7	6
438	Lowâ€molecular weight oligosaccharides from gum tragacanth (Astragalus gossypinus) ameliorate nonalcoholic fatty liver disease (<scp>NAFLD</scp>) in Wistar male rats. Food Science and Nutrition, 2023, 11, 765-777.	1.5	3
439	Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review. European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48, 1-10.	0.6	3

#	Article	IF	Citations
440	Phosphorylation of 17Î²-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice. Nature Communications, 2022, 13, .	5.8	17
441	Gutâ€“Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. Biology, 2022, 11, 1622.	1.3	16
442	Regulation of Cholesterol Metabolism by Phytochemicals Derived from Algae and Edible Mushrooms in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 13667.	1.8	6
443	Protein-driven membrane remodeling: Molecular perspectives from Flaviviridae infections. Biophysical Journal, 2023, 122, 1890-1899.	0.2	3
444	MAFLD: How is it different from NAFLD?. Clinical and Molecular Hepatology, 2023, 29, S17-S31.	4.5	52
445	Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese. Frontiers in Endocrinology, 0, 13, .	1.5	4
447	New Insights into the Basic and Translational Aspects of AMPK Signaling. Cells, 2023, 12, 206.	1.8	1
448	Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Frontiers in Endocrinology, 0, 13, .	1.5	0
449	Pathogenetic role of fetuin-A in formation of metabolic disorders and systemic inflammation in patients with non-alcoholic fatty liver disease. Modern Gastroenterology, 2022, , 5-11.	0.1	0
450	Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatology International, 2023, 17, 606-614.	1.9	8
451	Effect of Resveratrol on Pregnancy, Prenatal Complications and Pregnancy-Associated Structure Alterations. Antioxidants, 2023, 12, 341.	2.2	5
452	Activation of Granulocytes in Response to a High Protein Diet Leads to the Formation of Necrotic Lesions in the Liver. Metabolites, 2023, 13, 153.	1.3	0
453	The Link between NAFLD and Metabolic Syndrome. Diagnostics, 2023, 13, 614.	1.3	10
454	Bidirectional association between NAFLD and gallstone disease: a systematic review and meta-analysis of observational studies. Expert Review of Gastroenterology and Hepatology, 2023, 17, 283-293.	1.4	3
455	Efficacy of silymarin in patients with non-alcoholic fatty liver disease â€” the Siliver trial: a study protocol for a randomized controlled clinical trial. Trials, 2023, 24, .	0.7	3
456	Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity. Metabolites, 2023, 13, 531.	1.3	1
457	Microcystins Exposure Associated with Blood Lipid Profiles and Dyslipidemia: A Cross-Sectional Study in Hunan Province, China. Toxins, 2023, 15, 293.	1.5	1
485	Global liver transplantation: emerging trends and ethical challenges. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	0

#	Article	IF	Citations